Journal of Alzheimer's Disease最新文献_第5页

A sleep-based risk model for predicting dementia: Development and validation in a Korean cohort. 预测痴呆的基于睡眠的风险模型：韩国队列的发展和验证。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-07-01 Epub Date: 2025-05-08 DOI: 10.1177/13872877251340094

Hyukjun Lee, Ji Won Han, Seung Wan Suh, Hee Won Yang, Dae Jong Oh, Eunji Lim, Jin Shin, Bong Jo Kim, Dong Woo Lee, Jeong Lan Kim, Jin Hyeong Jhoo, Joon Hyuk Park, Jung Jae Lee, Kyung Phil Kwak, Seok Bum Lee, Seok Woo Moon, Seung-Ho Ryu, Shin Gyeom Kim, Ki Woong Kim

{"title":"A sleep-based risk model for predicting dementia: Development and validation in a Korean cohort.","authors":"Hyukjun Lee, Ji Won Han, Seung Wan Suh, Hee Won Yang, Dae Jong Oh, Eunji Lim, Jin Shin, Bong Jo Kim, Dong Woo Lee, Jeong Lan Kim, Jin Hyeong Jhoo, Joon Hyuk Park, Jung Jae Lee, Kyung Phil Kwak, Seok Bum Lee, Seok Woo Moon, Seung-Ho Ryu, Shin Gyeom Kim, Ki Woong Kim","doi":"10.1177/13872877251340094","DOIUrl":"10.1177/13872877251340094","url":null,"abstract":"BackgroundDementia is a major public health challenge, yet existing prediction models often overlook sleep-related symptoms, despite their known links to cognitive decline.ObjectiveTo develop and validate a four-year Dementia Risk Score (DRS) incorporating self-reported sleep-related symptoms with demographic and clinical factors to predict all-cause dementia, including Alzheimer's disease.MethodsData from 3082 Korean adults aged 60-79 years were analyzed. Predictors were selected using LASSO regression and included in a multivariate logistic regression model. A point-based scoring system, the DRS, was constructed from the model coefficients. Internal validation was conducted using bootstrapping and a separate dataset.ResultsThe DRS achieved robust predictive performance, with AUC values of 0.824 in the training set and 0.826 in the validation set. Key predictors included sleep disturbance, use of sleep medications, daytime dysfunction, leg discomfort, and urge to move legs.ConclusionsThe DRS provides a practical, scalable tool for predicting dementia risk, supporting community-based screening and early intervention. External validation is needed to confirm its broader applicability.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"280-292"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Circulating short chain fatty acids in Alzheimer's disease: A cross-sectional observational study. 循环短链脂肪酸在阿尔茨海默病中的作用：一项横断面观察研究。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-07-01 Epub Date: 2025-06-12 DOI: 10.1177/13872877251337773

Moira Marizzoni, Luigi Coppola, Cristina Festari, Delia Luongo, Dominic Salamone, Daniele Naviglio, Andrea Soricelli, Peppino Mirabelli, Marco Salvatore, Annamaria Cattaneo, Giovanni B Frisoni

引用次数: 0

An intelligent screener for mild cognitive impairment via integrated eye-tracking and the digital clock drawing test. 一种结合眼动追踪和数字时钟绘图测试的轻度认知障碍智能筛检器。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-06-30 DOI: 10.1177/13872877251350101

Jinyu Chen, Chenxi Hao, Xiaonan Zhang, Wencheng Zhu, Sijia Hou, Junpin An, Wenjing Bao, Zhigang Wang, Shuning Du, Qiuyan Wang, Guowen Min, Yarong Zhao, Yang Li

{"title":"An intelligent screener for mild cognitive impairment via integrated eye-tracking and the digital clock drawing test.","authors":"Jinyu Chen, Chenxi Hao, Xiaonan Zhang, Wencheng Zhu, Sijia Hou, Junpin An, Wenjing Bao, Zhigang Wang, Shuning Du, Qiuyan Wang, Guowen Min, Yarong Zhao, Yang Li","doi":"10.1177/13872877251350101","DOIUrl":"https://doi.org/10.1177/13872877251350101","url":null,"abstract":"BackgroundMild cognitive impairment (MCI) is a risk factor for dementia, and early screening is crucial for patient prognosis.ObjectiveTo construct an intelligent family screening model for MCI based on eye tracking (ET) and digital clock drawing tests (dCDT), to provide a simple and accurate screening tool for MCI.MethodsThis study included 618 cognitively normal participants and 179 patients with MCI, among whom demographic information and metrics from ET and dCDT were collected. One-way analysis of variance was applied to screen all variables (p < 0.05). Different feature sets constructed based on logistic regression and five machine learning methods (random forests, multilayer perceptron, support vector machines, extreme gradient boosting trees, and convolutional neural networks) were used to construct 36 MCI screening tools. Finally, the diagnostic efficacy of the models was evaluated based on the area under the receiver operating characteristic curve (AUROC), accuracy, sensitivity, and specificity.ResultsMultimodal features, namely demographics, dCDT, and ET, showed superior performance compared to models based on unimodal behavioral data with or without demographics. Among all algorithms, the random forest model based on all significant features performed the best, with an AUROC of 0.947.ConclusionsHerein, we integrated demographic information, eye tracking, and digital drawing clock tests to construct an MCI screening model that yielded superior classification performance. As a potential intelligent screening tool for MCI in the community, we aim to further build a multicenter external validation study to improve the model's generalizability.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251350101"},"PeriodicalIF":3.4,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing greater statistical power: Comprehensive evaluation of disease modifying treatment effects across all or multiple post-baseline visits compared to the last visit for Alzheimer's disease clinical trials. 利用更大的统计力量：与阿尔茨海默病临床试验的最后一次访问相比，对所有或多次基线后访问的疾病改善治疗效果进行综合评估。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-06-30 DOI: 10.1177/13872877251352189

Guoqiao Wang, Tianle Chen, John O'Gorman, Yan Li, CaiYan Li, Leonard Guizzetti, Brian Mangal, Whedy Wang, Shuang Wu, Dave Inman, Eric McDade, Randall J Bateman

{"title":"Harnessing greater statistical power: Comprehensive evaluation of disease modifying treatment effects across all or multiple post-baseline visits compared to the last visit for Alzheimer's disease clinical trials.","authors":"Guoqiao Wang, Tianle Chen, John O'Gorman, Yan Li, CaiYan Li, Leonard Guizzetti, Brian Mangal, Whedy Wang, Shuang Wu, Dave Inman, Eric McDade, Randall J Bateman","doi":"10.1177/13872877251352189","DOIUrl":"https://doi.org/10.1177/13872877251352189","url":null,"abstract":"BackgroundIn Alzheimer's disease (AD) clinical trials, efficacy inference is traditionally based on the last visit (e.g., 18 months). However, recent studies suggest that disease-modifying treatment effects may emerge as early as 3 months post-baseline.ObjectiveTo explore this further, our study aimed to assess the increased statistical power achieved by incorporating all or multiple post-baseline visits to estimate treatment effect, compared to relying solely on the last visit.MethodsWe developed explicit formulas for the basis functions of the natural cubic spline model, ensuring compatibility with standard SAS procedures. Through simulations using disease progression trajectories from Clarity-AD and TRAILBLAZER-ALZ 2 trials, we comprehensively evaluated various models in terms of power and type I error. Additionally, we offer SAS codes that to facilitate seamless implementation of different modeling approaches.ResultsSimulations based on ClarityAD and TRAILBLAZER-ALZ 2 disease trajectories demonstrated that models incorporating multiple or all post-baseline visits yield greater power than those using only the last visit, while maintaining Type I error control. Furthermore, when three post-baseline visits were included, adding more visits resulted in minimal power gains.ConclusionsOur findings support prioritizing statistical models that incorporate multiple or all post-baseline visits for treatment efficacy inference, as they offer greater efficiency than models relying solely on the last visit.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251352189"},"PeriodicalIF":3.4,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methanol extract from miracle fruit seeds mitigates Alzheimer's disease and enhance autophagy via suppressing the AKT/mTOR signal pathway. 神果种子甲醇提取物通过抑制AKT/mTOR信号通路减轻阿尔茨海默病并增强自噬。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-06-30 DOI: 10.1177/13872877251352545

Zi-Ting Shang, Xue-Yan Huang, Liu-Lin Xiong, Zu-Cai Xu, He-Xu Liu, Chang-Yin Yu

{"title":"Methanol extract from miracle fruit seeds mitigates Alzheimer's disease and enhance autophagy via suppressing the AKT/mTOR signal pathway.","authors":"Zi-Ting Shang, Xue-Yan Huang, Liu-Lin Xiong, Zu-Cai Xu, He-Xu Liu, Chang-Yin Yu","doi":"10.1177/13872877251352545","DOIUrl":"https://doi.org/10.1177/13872877251352545","url":null,"abstract":"Background: Alzheimer's disease (AD) is a neurodegenerative disease. In previous study, we discovered that methanol extract of miracle fruits seeds (MFSs) had a therapeutic effect on AD model mice. Objective: In this research, we aimed to study the role of MFSs in alleviating amyloid-β (Aβ) deposition and further explore the possible mechanism of action of MFSs. Methods: We used behavioral tests and various immunolabeling techniques on two AD model (Aβ transgenic model strain CL4176 of Caenorhabditis elegans and the 3 × Tg-AD mice). Results: In CL4176, MFSs (10 μg/mL) could effectively alleviate the paralysis caused by Aβ, the Aβ plaques were significantly reduced, the transcription levels of Aβ, age-1, akt-1 and mTOR genes were significantly downregulated, and the transcription of autophagy-related gene lgg-1 was enhanced. The cognitive function of mice in the MFSs group was improved, which was related to reduced synapse loss and Aβ-positive neurons in the brain. Meanwhile, the transcription levels of amyloid-β protein precursor (AβPP), Tau, Akt and mTOR were significantly reduced. The protein expressions of PSD95, SYN1, LC3II/I and Beclin-1 were significantly increased, and the value of p62/SQSTM1, p-AKT/AKT, p-mTOR/mTOR were reduced. Conclusions: MFSs significantly alleviates Aβ deposition in CL4176 and mice. The mechanism by which it improves cognitive function in AD mice may be related to enhanced autophagy regulated by the Akt/mTOR signaling pathway.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251352545"},"PeriodicalIF":3.4,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blood biomarkers of Alzheimer's disease in Australians habitually consuming various plant-based diets. 习惯食用各种植物性饮食的澳大利亚人阿尔茨海默病的血液生物标志物。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-06-30 DOI: 10.1177/13872877251351549

Shaun Eslick, Grace Austin, Jessica Ja Ferguson, Manohar L Garg, Christopher Oldmeadow, Ralph N Martins

{"title":"Blood biomarkers of Alzheimer's disease in Australians habitually consuming various plant-based diets.","authors":"Shaun Eslick, Grace Austin, Jessica Ja Ferguson, Manohar L Garg, Christopher Oldmeadow, Ralph N Martins","doi":"10.1177/13872877251351549","DOIUrl":"https://doi.org/10.1177/13872877251351549","url":null,"abstract":"BackgroundEvidence suggests that plant-based diets (PBDs) may be protective against neurodegenerative diseases such as Alzheimer's disease (AD).ObjectiveThis study examined associations between blood-based AD biomarkers in individuals 30-75 years without current or diagnosed cardiovascular disease following different PBDs versus regular meat-eating diets (RMEs).MethodsThis secondary analysis of the Plant-based Diets study measured Aβ1-42/Aβ1-40, p-tau181, NFL, and GFAP in 237 plasma samples using SIMOA from individuals following vegan, pesco-vegetarian (PVs), lacto-ovo vegetarian (LOVs), semi-vegetarian (SVs), or RME diets. Multivariable regression adjusted for age and sex.ResultsFollowing adjustments for age and sex, plasma Aβ1-42/Aβ1-40 ratio was significantly higher in PVs 0.011 (CI: 0.006, 0.016, p < 0.01), LOVs 0.011 (CI: 0.007, 0.016, p < 0.01) and SVs 0.015 (0.009-0.020, p < 0.01) groups compared to RMEs. Plasma p-tau181 was significantly higher in PVs 3.4 (CI: 0.4-6.4, p < 0.05) and LOVs 7.1 (CI: 2.5, 11.8, p < 0.01), NFL higher in PVs 5.2 (CI: 1.6, 8.7, p < 0.01) and LOVs 4.0 (CI: 1.6, 6.5, p = 0.01), and GFAP higher in PVs 26 (CI: 6, 47, p < 0.05) and LOVs 21 (5, 367, p = 0.01), all compared to RMEs.ConclusionsThis analysis suggests that PBDs may be associated with blood-based AD biomarkers. Higher Aβ1-42/Aβ1-40 levels in PV, LOV and SV dietary patterns compared to RMEs could indicate lesser amyloid burden, but elevated levels of other AD biomarkers in some PBDs warrant further investigation into nutrient-specific roles in AD pathology.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251351549"},"PeriodicalIF":3.4,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of corrections for renal function on plasma phosphorylated tau performance for Alzheimer's disease. 纠正肾功能对阿尔茨海默病血浆磷酸化tau表现的影响。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-06-30 DOI: 10.1177/13872877251350718

Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, Kazushi Suzuki, Takeshi Iwatsubo

{"title":"Effect of corrections for renal function on plasma phosphorylated tau performance for Alzheimer's disease.","authors":"Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, Kazushi Suzuki, Takeshi Iwatsubo","doi":"10.1177/13872877251350718","DOIUrl":"https://doi.org/10.1177/13872877251350718","url":null,"abstract":"BackgroundBlood-based biomarkers (BBMs), including plasma phosphorylated tau (pTau), have been considered as a promising, less-invasive tool for detecting Alzheimer's disease (AD) pathology in real-world applications. Plasma pTau levels are known to be elevated in individuals with chronic kidney disease, which may require caution when corrected for renal function since it alters testing performance-decreased sensitivity and increased specificity.ObjectiveWe aimed to quantify how correcting for renal function affects BBM test performance.MethodsWe analyzed plasma pTau181 and pTau217 measured by multiple platforms, using data from our ongoing trial-ready cohort study in Japan and the ADNI study, in which approximately 30% of participants had mild or moderate renal impairment (eGFR < 60). We compared models with and without renal correction to predict amyloid PET positivity status.ResultsCompared to no correction, adjusting for renal function reduced sensitivity by 0.06-0.07 and increased specificity by 0.04-0.10. It also slightly increased positive predictive value, negative predictive value, balanced accuracy, and area under the curve-each by less than 0.02. These shifts by correction were more pronounced when the participant prevalence of those with renal function was higher, though mainly for sensitivity and specificity.ConclusionsOur findings demonstrated that applying renal function correction decreases sensitivity and increases specificity of BBM test depending on the prevalence of renal impairment, without undermining overall prediction accuracy. They emphasize the need of considering the background characteristics of the target population when interpreting BBM performances in the real-world settings.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251350718"},"PeriodicalIF":3.4,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Electroencephalogram features support the retrogenesis hypothesis of Alzheimer's disease: Exploratory comparison of brain changes in aging and childhood. 脑电图特征支持阿尔茨海默病的退化假说：老年期和儿童期大脑变化的探索性比较

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-06-30 DOI: 10.1177/13872877251352119

João Areias Saraiva, Martin Becker, Martin Dyrba, Burcu Bölükbaş, Enrico Michele Salamone, Claudio Babiloni, Michael Kölch, Harald Hampel, Stefan Teipel, Thomas Kirste, Christoph Berger

{"title":"Electroencephalogram features support the retrogenesis hypothesis of Alzheimer's disease: Exploratory comparison of brain changes in aging and childhood.","authors":"João Areias Saraiva, Martin Becker, Martin Dyrba, Burcu Bölükbaş, Enrico Michele Salamone, Claudio Babiloni, Michael Kölch, Harald Hampel, Stefan Teipel, Thomas Kirste, Christoph Berger","doi":"10.1177/13872877251352119","DOIUrl":"https://doi.org/10.1177/13872877251352119","url":null,"abstract":"BackgroundThe retrogenesis hypothesis (RH) suggests that the functional and cognitive decline observed in Alzheimer's disease dementia mirrors in reverse order the brain development during childhood and adolescence.ObjectiveEquivalent electroencephalogram (EEG) patterns between older adults across different cognitive decline stages and children across different brain maturation stages were directly compared.MethodsTo capture the complex patterns that allow for such a comparison, a regression model was trained on EEG data from N = 510 older adults, at different stages of cognitive reserve, to identify EEG markers predictive of global cognitive status. The model was then applied on the same EEG markers of N = 696 children across different ages.ResultsThe model predicted MMSE scores with an average error of 2.53 and R2 of 0.80. When applied to children, predictions correlated positively with age (r = 0.73). Key predictors of cognitive function concordant in both populations were theta coherence (right frontal-left temporal/parietal), temporal Hjorth complexity, and beta edge frequency, supporting the RH.ConclusionsThese EEG features were inversely associated between older adults and children, supporting a functional underpinning of the retrogenesis model of dementia. Clinical validation of these biomarkers could favor their use in the continuous monitoring of cognitive function.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251352119"},"PeriodicalIF":3.4,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Value of muscle strength in improving the predictive capability for cognitive decline in older women by established risk factors: A prospective cohort study in the Otassha Study. 肌肉力量在通过确定的危险因素提高老年妇女认知能力下降的预测能力中的价值：奥塔沙研究的一项前瞻性队列研究。

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-06-30 DOI: 10.1177/13872877251351626

Takahisa Ohta, Narumi Kojima, Sho Hatanaka, Takashi Shida, Yosuke Osuka, Hiroyuki Sasai

{"title":"Value of muscle strength in improving the predictive capability for cognitive decline in older women by established risk factors: A prospective cohort study in the Otassha Study.","authors":"Takahisa Ohta, Narumi Kojima, Sho Hatanaka, Takashi Shida, Yosuke Osuka, Hiroyuki Sasai","doi":"10.1177/13872877251351626","DOIUrl":"https://doi.org/10.1177/13872877251351626","url":null,"abstract":"BackgroundWith a growing aging global population, dementia has become an important public health concern. However, few predictive models of cognitive decline include muscle strength as a variable.ObjectiveThis study aimed to assess whether handgrip and knee extensor muscle strengths could be associated with cognitive decline in older Japanese women and to examine the potential contribution of these measurements to established dementia onset prediction models.MethodsA prospective cohort study was conducted involving the data analyzed from 787 community-dwelling aged 65 years and older women, originally from the \"Otassha Study.\" The baseline handgrip and knee extensor muscle strengths were measured. Cognitive decline was defined as a decrease of three or more points from the baseline score of the Japanese version of the Mini-Mental State Examination. Multivariate analyses were performed adjusting for various potential confounding factors, and interaction effects were explored. The discriminative performances of the extended models were evaluated using receiver operating characteristic (ROC) curve analysis.ResultsNotably, lower handgrip and knee extensor muscle strengths were associated with cognitive decline in participants ≥ 75-year-old. Adding handgrip strength to the established models slightly improved the predictive performance, thereof; however, adding knee extensor muscle strength did not.ConclusionsOur study revealed the values of handgrip and knee extensor muscle strengths were associated with cognitive decline among women aged 75 years and older. Incorporating handgrip strength into predictive models enhanced their accuracy, which highlighted the importance of assessing muscle strength to predict cognitive decline in older women.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251351626"},"PeriodicalIF":3.4,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between cardiovascular-kidney-metabolic syndrome and risk of low cognitive function in older adults: Data from the NHANES 2011-2014. 老年人心血管-肾代谢综合征与认知功能低下风险之间的关系：来自NHANES 2011-2014的数据

IF 3.4 3区医学

Journal of Alzheimer's Disease Pub Date : 2025-06-27 DOI: 10.1177/13872877251352204

Xinde Zheng, Shuzhi Lin, Zefeng Cai, Jilin Li

{"title":"Association between cardiovascular-kidney-metabolic syndrome and risk of low cognitive function in older adults: Data from the NHANES 2011-2014.","authors":"Xinde Zheng, Shuzhi Lin, Zefeng Cai, Jilin Li","doi":"10.1177/13872877251352204","DOIUrl":"https://doi.org/10.1177/13872877251352204","url":null,"abstract":"BackgroundCardiovascular-kidney-metabolic (CKM) syndrome was associated with high risk of adverse health outcomes. However, the relationship between CKM syndrome and risk of low cognitive function remains underexplored.ObjectiveTo evaluate the association between CKM syndrome and low cognitive function risk among older adults.MethodsThis study included 2158 participants aged 60 years or older from the NHANES 2011-2014. Cognitive function was assessed using the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) test, Digit Symbol Substitution Test (DSST), and Animal Fluency Test. Weighted multivariable logistic regression models were used to examine the association between different stages of CKM syndrome and low cognitive function risk.ResultsAmong the 2158 participants, 486 (22.5%) for the CERAD test, 492 (22.8%) for the DSST, and 456 (21.1%) for the Animal Fluency Test were diagnosed with low cognitive function. Compared with participants at CKM syndrome Stage 0, the multivariate-adjusted odds ratios (OR) and 95% confidence intervals (CI) for low cognitive function assessed by CERAD test in Stages 1 to 4 were 0.76 (0.23, 2.98), 1.56 (0.79, 3.72), 1.72 (1.02, 4.10), and 2.97 (1.15, 5.42), respectively. For the DSST, the OR and 95% CI in Stages 1-4 were 0.75 (0.34, 3.42), 1.21 (0.65, 2.95), 1.30 (1.04, 3.23), and 2.21 (1.05, 4.92), respectively. No significant association was found between CKM syndrome and low cognitive function for the Animal Fluency Test.ConclusionsOlder adults at CKM stages 3-4 showed poorer cognitive performance, particularly in episodic memory, processing speed, and attention, compared to those at stage 0.","PeriodicalId":14929,"journal":{"name":"Journal of Alzheimer's Disease","volume":" ","pages":"13872877251352204"},"PeriodicalIF":3.4,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0